COM701
Monoclonal antibody
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03667716 NCT03667716 · Ovarian Cancer Registry: NCT03667716 | 1 | Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs). (DLT evaluation window in the 1st cycle (21 or 28 days).); Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab). (Approximately 2 year.) 2024-01-30 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
MAIA-ovarian NCT06888921 · Ovarian Cancer Registry: NCT06888921 | 1/2 | To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOC (From the date of randomization until the date of disease progression, or date of death from any cause whichever occurs first, assessed up to 2 years) 2027-03 | In progress: results expected 1 Mar 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Ovarian Cancer: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| COM701: this drug | Phase 1/2 | Monoclonal antibody | PVRIG (CD112R) | not yet graded | No reviewed efficacy summary in this indication | |
| Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack) | Approved | Small molecule | MEK1/2 and RAF (CRAF, BRAF), FAK | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Mirvetuximab Soravtansine (Elahere) | Approved | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Approved | Small molecule | PARP1/2 | Reliable signal | NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Reliable signal | Featured results are non-efficacy only in this race | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK 5733584 | Phase 3 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| INCB123667 | Phase 3 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Raludotatug Deruxtecan | Phase 3 | Antibody–drug conjugate | CDH6 (Cadherin-6) | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sofetabart Mipitecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Torvutatug Samrotecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Birinapant | Phase 2 | — | IAP (inhibitor of apoptosis) proteins | not yet graded | No reviewed efficacy summary in this indication | |
| Ixotatug Vedotin | Phase 2 | Antibody–drug conjugate | Claudin 6 (CLDN6) | not yet graded | No reviewed efficacy summary in this indication | |
| Stenoparib | Phase 2 | Small molecule | PARP1/2, Tankyrase 1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5668 | Phase 1/2 | Multispecific antibody | MUC16 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | not yet graded | No reviewed efficacy summary in this indication | |
| TUB-040 | Phase 1/2 | Antibody–drug conjugate | NaPi2b (sodium-dependent phosphate transporter, SLC34A2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ubamatamab | Phase 1/2 | Monoclonal antibody | MUC16 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| 27T51 | Phase 1 | Cell therapy | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-901 | Phase 1 | Undisclosed | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| APG-2449 | Phase 1 | Small molecule | FAK / ALK / ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| IDE-161 | Phase 1 | Small molecule | PARG | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb541 | Phase 1 | Multispecific antibody | Claudin 6 (CLDN6) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Luveltamab Tazevibulin | Discontinued | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Remzistotug | Discontinued | Monoclonal antibody | PVRIG (CD112R) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow COM701 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.